How many insider trades does FilingIQ track for PRLD?

FilingIQ tracks 178 Form 4 insider transactions for PRLD (Prelude Therapeutics Inc), covering filings from Sep 29, 2020 onwards. 0 of those are dated within the last 90 days.

Are PRLD insiders net buyers or net sellers?

Across the full Form 4 history for PRLD, 41 transactions (23%) were open-market purchases and 67 (38%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PRLD insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is PRLD in?

Prelude Therapeutics Inc (PRLD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $295.47M.

PRLD insider trading

NasdaqGS Healthcare

Prelude Therapeutics Inc: insider trade history from SEC Form 4 filings.

Total Form 4 trades

178

Last 90 days

Buys / sells

23% / 38%

Market cap

$295.47M

About Prelude Therapeutics Inc

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Company website: preludetx.com

PRLD insider activity at a glance

FilingIQ tracks 178 insider transactions for PRLD in filings since Sep 29, 2020. The most recent transaction is dated Apr 27, 2026.

Across the full history, 41 open-market purchases and 67 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PRLD insider trades is 56.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PRLD trades on FilingIQ Raw filings on SEC EDGAR

Latest PRLD Form 4 filings

BAKER BROS. ADVISORS LP

A Jun 10, 2026

Morris Charles Q Chief Medical Officer

A May 4, 2026

RA CAPITAL MANAGEMENT, L.P.

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for PRLD?: FilingIQ tracks 178 Form 4 insider transactions for PRLD (Prelude Therapeutics Inc), covering filings from Sep 29, 2020 onwards. 0 of those are dated within the last 90 days.
Are PRLD insiders net buyers or net sellers?: Across the full Form 4 history for PRLD, 41 transactions (23%) were open-market purchases and 67 (38%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PRLD insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is PRLD in?: Prelude Therapeutics Inc (PRLD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $295.47M.

Methodology & sources

Every PRLD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.